Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study
B. Singer(Missouri Baptist Medical Center), Sibyl Wray, Jiwon Oh(St. Michael's Hospital), Seth Levin(Biogen (United States)), Matthew Scaramozza(Ono Pharmaceutical (United States)), Mark Gudesblatt(Urology Associates), Mark S. Freedman(University of Ottawa), Hailu Chen(Biogen (United States)), Krzysztof Selmaj(University of Warmia and Mazury in Olsztyn), Donald Negroski, Sai L. Shankar(Biogen (United States)), Ralf Gold(University Hospitals of the Ruhr-University of Bochum), Douglas L. Arnold(University of Oxford), Robert T. Naismith(Washington University in St. Louis), Elżbieta Jasińska(Collegium Medicum in Bydgoszcz), Florian Then Bergh(Leipzig University), Christopher LaGanke(Urology Associates), Jelena Drulović(University of Belgrade), Wanda Castro-Borrero(Biogen (United States)), Ting Wang(Xijing Hospital), Annette Wundes(University of Washington Medical Center), Tjalf Ziemssen(University Hospital Carl Gustav Carus), Miguel Ángel Hernández Pérez(Hospital Universitario Nuestra Señora de Candelaria)
Cited by 23
Related Papers
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
|Brain|2011|1.2k
Multiple Sclerosis Severity Score
|Neurology|2005|957